AI In Pharma & Medicine: What’s In Store For 2024?

Over the past decade, artificial intelligence has become deeply integrated into various facets of pharmaceutical and medical research, as well as clinical practice. Fueled by extensive datasets and advanced algorithms, AI is showcasing its potential to drive innovation and enhance patient outcomes. As this transformative technology continues its rapid evolution, the year 2024 is poised to be a pivotal moment, marking substantial growth in AI’s role and impact within the healthcare sector.

AI is reshaping the landscape of medical research by playing a crucial role in drug discovery and refining individualized treatment approaches. Its capacity to analyze vast and intricate datasets holds significant promise, expediting the scientific process and uncovering novel insights that could hasten the delivery of life-saving therapies. Simultaneously, AI presents unprecedented opportunities to advance precision medicine, facilitating more tailored healthcare solutions that align with an individual’s unique genetic profile and characteristics. With the increasing advancements of AI tools, these applications are expected to mature and garner broader acceptance across the healthcare industry.

2023 Key AI Developments In Pharma

Increased Investment in AI for Drug Discovery Startups

Significant investments and funding were observed in AI-driven startups focused on drug discovery. Notable late-stage funding rounds were secured by companies such as Anthropic ($153 million), Exscientia ($540 million), and insitro ($460 million), indicating a sustained growth trajectory in this domain.

Advancement of AI-Discovered Drug Candidates into Clinical Trials

AI-driven drug discovery platforms, exemplified by companies like Exscientia, Insitro, and BenevolentAI, achieved a pivotal milestone by progressing AI-designed drug candidates into Phase 1 and Phase 2 clinical trials. These trials encompassed a range of conditions, including cancer, fibrosis, and metabolic diseases, signifying the initiation of human testing for the first wave of AI-discovered drugs.

Expansion of AI Capabilities by Big Pharma

Major pharmaceutical players such as 阿斯利康 , 荷商葛蘭素史克藥廠 , Sanofi , 默克 , and 辉瑞 significantly expanded their internal AI capabilities. These companies made substantial investments in building dedicated AI teams and technologies. Concurrently, they forged new partnerships with AI-driven drug discovery startups, enhancing their collaborative efforts to augment internal initiatives.

FDA Guidance on Regulating AI/ML Tools

The U.S. Food and Drug Administration ( FDA ) has enhanced regulatory transparency concerning AI/ML tools, permitting certain alternatives to traditional animal and human trials. The agency has disseminated guidance outlining the rationale for Software as a Medical Device (SaMD) based on AI/ML. Furthermore, the FDA has released guidance endorsing the utilization of digital twins and synthetic data as potential substitutes for certain pre-clinical animal studies and early-phase human trials, mitigating risks and expediting the development process. These measures have effectively lowered barriers to AI solutions, contributing to the acceleration of drug discovery timelines.

Diversification of AI Applications

AI’s application extended well beyond drug discovery, encompassing various areas throughout the value chain. Tools designed for clinical trials, including patient recruitment and monitoring, regulatory compliance, medical affairs, market access and pricing, market research, and sales and marketing witnessed notable growth. This diversification highlighted the versatility of AI across multiple facets of the pharmaceutical industry.

Statistics also highlight the growing adoption of AI – a survey found over 75% of pharma executives plan to apply AI to speed drug discovery by 2025. Total investment in AI for healthcare surpassed $5 billion according to CB Insights , up 30% from 2023.

These developments collectively underscore the dynamic and evolving role of AI in pharmaceuticals, reflecting advancements in technology, regulatory frameworks, and collaborative efforts between industry players.

2024 Emerging Trends Of AI In Pharma

Digital Twins and Synthetic Data Use Expands

Digital twins and synthetic data are transforming drug discovery and development, offering virtual replicas of physical entities like drug molecules, patients, or clinical trials to simulate real-world scenarios. Pharma companies leverage these technologies, using AI for synthetic data generation, to enhance R&D efficiency and cost-effectiveness.

Digital twins of drug molecules enable rapid in-silico testing, expediting the identification of promising candidates. For instance, Anthropic reduced the time to discover a potential drug for retinal diseases from years to days through digital twin simulations, training AI models to predict drug properties without physical experiments.

Synthetic versions of patient health records, generated using AI, address data sparsity and privacy concerns. Companies augment limited real-world datasets at scale for training advanced AI/ML models. PBC Linear creates synthetic datasets mimicking the statistical properties of actual patient records while preserving privacy, aiding applications from clinical trial recruitment to drug safety monitoring.

Increasing Use of Real-World Data:

Real-world data (RWD), sourced from electronic health records, medical claims and various other channels, is assuming an increasingly vital role in both drug development and regulatory decision-making.

Anticipated for the year 2024 are innovative applications of RWD that will:

1. Provide valuable insights supporting the design of clinical trials, focusing on optimal patient populations and endpoints.

2. Generate real-world evidence concerning the effectiveness and safety of drugs beyond traditional trial environments.

3. Drive observational studies targeting patient subsets that are challenging to recruit.

4. Facilitate continuous monitoring of drugs post-approval through the application of real-time analytics.

As the analytics of RWD mature, there exists the potential to streamline regulatory pathways and broaden access to novel therapies. However, it is imperative to rigorously assess data quality and implement appropriate controls to ensure the validity of insights derived from RWD. The widespread integration of RWD through the capabilities of AI holds the promise of a transformative impact on healthcare.

AI in Drug Discovery and Development Continues to Grow

AI has emerged as a powerful catalyst for expediting the drug discovery process. By meticulously analyzing extensive datasets encompassing chemical, genomic, and clinical trial information, machine learning facilitates the identification of novel drug targets and candidate molecules by researchers.

A noteworthy study published in Nature Biotechnology revealed that AI has the potential to reduce the time required for target identification by more than 70%, surpassing the efficiency of traditional methods. Anticipated advancements in our datasets and algorithms are poised to propel a greater number of AI-identified compounds into pre-clinical testing stages by 2024.

According to a report from the analytics firm Clarivate , the integration of AI and machine learning could potentially truncate typical drug development timelines by as much as 10-15 years. This transformative capability holds the promise of addressing the urgent need for more efficacious treatments across a spectrum of diseases. Despite the existing challenges related to data quality and model performance, the outlook for AI revolutionizing drug discovery through extensive analytics remains exceptionally promising.

AI in Clinical Trial Optimization Continues to Grow

AI is showcasing notable potential in enhancing the optimization of clinical trial design and recruitment processes. Utilizing machine learning, it becomes possible to discern patient populations that are most likely to derive benefits from a specific intervention, leveraging advanced analytics of genetic and other personal health data. This approach facilitates more streamlined trial execution by minimizing variability in outcomes. Additionally, AI demonstrates the capability to expedite enrollment by systematically matching electronic medical records against trial eligibility criteria at scale.

A study conducted by Anthropic revealed that this AI-driven approach identified up to 30% more eligible patients compared to traditional recruitment methods. If these applications prove effective in reducing costs through enhanced operational efficiency and recruitment processes, they could significantly expedite the delivery of promising new therapies to patients. In the coming year, 2024, we anticipate increased real-world testing of AI applications, further validating their ability to support optimized trial conduct and showcasing the tangible value of these emerging technologies.

AI Use in Enhancing Personalized Medicine Continues to Grow

In the year 2024 and beyond, the integration of AI is poised to significantly enhance the scope of personalized and precision medicine. Machine learning algorithms are instrumental in navigating through an individual’s genomic data, health records, lifestyle factors and more, thereby generating highly tailored treatment recommendations.

An illustrative example of AI’s current impact is its contribution to oncologists in determining the most effective therapies for cancer patients based on their unique tumor profiles. With the continuous exponential growth of genomic and health datasets, AI is anticipated to unveil even more profound insights. In parallel, pharmaceutical companies are increasingly employing AI to develop drugs precisely targeting specific genetic mutations or biomarkers. In 2024, an escalation in the prevalence of AI-powered tools is expected, aiding physicians in crafting personalized care plans, selecting drugs and determining dosages tailored to the specific needs of each patient.

The rise in companion diagnostics alongside the introduction of new precision therapies underscores the critical role of AI in analyzing vast amounts of biomarker and outcomes data essential for optimizing treatment protocols. While challenges related to regulation and adoption persist, 2024 holds the potential to be a breakthrough year for AI-driven personalized medicine, gradually evolving into a standard clinical practice.

AI Remote Patient Monitoring

AI-driven remote monitoring is gaining traction. AI agents are being used for remote patient monitoring but this is not the only AI being used for this. Smart devices and wearables track vital signs, symptoms and activity, automatically alerting healthcare providers to anomalies. AI algorithms analyze data for early disease detection and clinical decision-making. For instance, Anthropic’s AI tool uses 苹果 Watch data to diagnose heart conditions.

As clinical evidence expands, AI clinical decision support systems (CDSS) integration into provider workflows is set to grow. These tools, powered by deep learning from electronic health records, identify at-risk patients, recommend treatment plans and predict outcomes based on individual profiles. By 2024, AI promises more proactive, predictive, preventive, and participatory healthcare in virtual care, population health and precision medicine.

Increasing Regulatory Compliance Using AI

In a world with expensive consequences for non-compliance, AI stands poised to transform the regulatory affairs landscape by automating routine tasks (e.g. AI-driven tools can automatically categorize and label various document types, guaranteeing completeness and accuracy in each submission), offering predictive insights (e.g. AI can scrutinize vast datasets to recognize patterns in regulatory alterations, empowering businesses to act proactively rather than reactively), simplifying global operations (e.g. an AI system adept in comprehending distinct regulatory frameworks can efficiently guide firms through these complexities and translating and modifying documents to adhere to region-specific mandates) and fortifying data integrity (e.g. AI algorithms can provide robust encryption techniques and trace data lineage, ensuring compliance with stringent regulations such as GDPR). By integrating AI into their workflows, pharmaceutical companies can anticipate more efficient, precise and secure regulatory compliance.

Increasing AI Use Throughout the Value Chain

Discovery, R&D, clinical trials and regulatory are not the only areas in which AI is making an impact and continuing to grow. We are witnessing AI being used in every part of the value chain including supply chain, medical affairs, pharmacovigilance, market access, integrated insights and sales and marketing.

AI Agents Gain Traction

In 2024, Autonomous AI agents which are essentially AI-powered computer programs that can operate independently and make decisions on behalf of humans. AI agents are entities designed to perceive their environment and take actions to achieve specific goals. These agents can be software-based or physical entities built using artificial intelligence techniques. In healthcare, we are already witnessing autonomous agents performing a variety of tasks, such as diagnosing diseases and monitoring patient conditions but this is the tip of the iceberg. AI agents will revolutionize many pharma processes. Anything humans now do can, and will, be at least partially handled by an AI agent. However, numerous processes humans used to do have already been completely taken over by AI agents and this trend will increase.

AI in Healthcare Delivery Grows

In the upcoming year, AI is set to significantly enhance healthcare delivery and accessibility through workforce-augmenting applications. Virtual assistants, armed with natural language processing, efficiently handle patient queries, allowing clinicians to focus on complex cases. AI plays a key role in developing remote patient monitoring tools utilizing wearables and connected devices, expected to gain broader use in 2024. These tools can extend care access for chronic patients in underserved areas by reducing the need for in-person visits.

AI’s impact on healthcare delivery also extends to diagnostic support systems. Analyzing medical images, vital signs and diagnostic data, AI algorithms empower quicker and more precise diagnoses, especially vital in regions with a shortage of physicians.

As AI technology advances and garners more clinical evidence, the implementation of AI-powered diagnostic tools in 2024 holds promise for addressing disparities in equitable healthcare access. Fully integrated, these tools have the potential to bridge gaps and significantly contribute to ensuring broader and more uniform healthcare access for diverse populations.

Increasing AI Acceptance and Use from Regulators:

Global regulatory bodies, including the FDA and EMA, acknowledge the potential benefits and associated risks of AI applications in healthcare. Throughout 2024, these agencies will persist in offering guidance aimed at facilitating the responsible development and evaluation of AI-powered medical technologies. There exists a prospect for AI to contribute to the streamlining of regulatory processes.

An illustrative example is the potential application of machine learning to enhance the collection, management and analysis of pre-clinical and clinical trial data. This optimization process has the potential to construct robust evidence packages for submission and approval. By efficiently extracting key insights from extensive datasets, AI may play a role in expediting the regulatory review of new drugs and devices. Pilot programs exploring these possibilities are already in progress.

AI Partnerships and Investments

Major pharmaceutical companies are increasingly recognizing the imperative of extensive collaboration with external innovators to maintain a competitive edge in the AI landscape. Anticipated in 2024 is a heightened commitment from large pharmaceutical firms to augment their AI venture funding and engage in strategic partnerships with startups.

A notable illustration of this trend is 强生公司 ’s recent $5 billion investment in kHealth , an AI-driven digital health firm. These partnerships serve as a mechanism for pharmaceutical giants to tap into cutting-edge developments occurring beyond their organizational boundaries, ensuring they remain at the forefront of innovation.

Moreover, collaborations provide mutual benefits by enabling startups in the healthcare and drug discovery sectors to access extensive proprietary industry data and the potential for substantial scaling. As the AI landscape undergoes rapid evolution, it is expected that more major pharmaceutical players will actively pursue strategic alliances. This trajectory may also manifest in increased merger and acquisition (M&A) activities, exemplified by 百时美施贵宝 ’s 2021 acquisition of Myriad Genetics ’ oncology diagnostic business. Recognizing the pivotal role of AI, global partnerships across both public and private sectors will be paramount for propelling the next wave of innovation in 2024 and beyond.

Challenges and Ethical Considerations of AI

As AI technology progresses, ensuring its safe and responsible development is critical. Addressing concerns about data privacy, accuracy and bias during machine learning training in healthcare datasets poses a significant challenge. Thoroughly evaluating AI systems is essential to prevent unfair outcomes. Overcoming technical challenges related to data quality, model performance and explainability is equally important.

Regulatory bodies advocate for transparency in AI systems, demanding decisions understandable to humans. ?Given much of the earlier AI was “black box” algorithms, interpreting their outputs becomes vital although now more and more we have explainable “white box” AI. In 2024, as AI applications mature, building and maintaining public trust in their thoughtful design is an ongoing process that White Box AI goes some way to solve.

Adhering to principles like informed consent, accountability, and oversight is pivotal for responsible innovation. Consistent commitment to these principles ensures that AI developments align with ethical considerations, contributing to the responsible evolution of this transformative technology.

Societal Impacts

Responsibly deployed AI has the potential to greatly benefit society, especially in healthcare. It can significantly boost productivity by streamlining administrative tasks and clinical workflows. For example, AI assistants can cut down documentation time, allowing clinicians to focus more on direct patient care. Even small efficiency improvements across the healthcare system can lead to substantial economic savings, potentially reinvested to expand access to essential services. And in pharma, by leveraging AI effectively we can essentially cut 60-70% of the time and cost of bringing a drug to market, and these savings can be passed on to the healthcare systems.

AI’s impact extends to precision medicine and remote monitoring, promising better health outcomes and potentially reducing mortality rates. Addressing chronic illnesses through personalized AI-driven care also offers the prospect of controlling rising treatment costs. As predictive analytics guide more preventative care approaches, the societal benefits of AI-driven personalized care reach beyond individual well-being to benefit entire populations.

The Future of AI in Healthcare

In the next decade, AI’s role in healthcare is set to expand significantly, driven by rapid technological advancements. Expectations include deeper integration with IoT and virtual/augmented reality, enabling AI to play a key role in continuous remote patient monitoring. This integration is likely to extend into new therapeutic areas, beyond oncology and cardiology.

AI startups are already applying machine learning to develop digital therapeutics for most conditions including Alzheimer’s, cardiovascular conditions, diabetes, respiratory, hearing, vision, pain, addiction, sleep and mental health to name but a few existing applications. Additionally, AI-powered tools in public health programs can predict disease outbreaks, track epidemiological trends and monitor population health indicators, aiding effective resource allocation and cost-efficient prevention strategies.

The promising future of AI in healthcare depends on continued research and responsible development practices. Emphasizing ethical considerations and ongoing advancements is crucial to fully unlock AI’s transformative capabilities in healthcare.

Conclusion

In 2024, AI is poised to persist in its transformative role within all areas within the pharma value chain as well as in patient care, enhancing processes with heightened intelligence, efficiency and compliance. The integration of digital technologies will expedite drug discovery processes, concurrently upholding stringent regulatory standards. Additionally, intelligent agents and assistants are set to revolutionize healthcare delivery by introducing more personalized, remote, and predictive care models. The trajectory of medicine and drug development appears promising with the continued advancements in artificial intelligence.

At?Eularis, we are here to ensure that AI and FutureTech underpin your pharma success in the way you anticipate they can, helping you achieve AI and FutureTech maturation and embedding it within your organizational DNA.

If you need help to leverage AI to identify how to leverage generative AI into your leadership plan to increase operational efficiencies and speed up revenue growth, see more about what we do in this area here.?

For more information, contact Dr. Andree Bates?[email protected].

Listen to the AI for Pharma Growth Podcast on?

Apple here

Spotify here